Currently, the number of patients affected with hormone refractory breast cancer is growing. This can be attributed to the accelerating number of hormone therapies, which have made breast cancer resistant to most of these therapies. The global market for hormone refractory breast cancer or hormone-resistant breast cancer is restrained by the lack of suitable treatment. However, a new finding provides fresh hope for millions of patients who have been diagnosed with oestrogen receptor positive breast cancer. According to this finding, 70% of breast cancer patients have oestrogen receptor positive cancer and a majority of these patients respond well to therapies containing anti-oestrogen. Nevertheless, within 15 years, 50% of these patients will relapse and eventually die from the condition. If the clinical trials of this new drug prove successful, then such a treatment could help patients by shutting down tumors at an early stage. Development of such groundbreaking drugs for hormone refractory breast cancer will significantly fuel the growth of the market in the coming years.
The research study on hormone refractory breast cancer market has been prepared using a mix of primary and secondary research to bring forth valuable market estimates and forecasts. Furthermore, a correlation, regression, and time-series analysis in the report has been used to provide the key industry dynamics. Additionally, a detailed industry evaluation with qualitative and quantitative analysis has been presented in the report. Overview of the global hormone refractory breast cancer market According to WHO, breast cancer is the most common type of cancer affecting women from both developing and developed nations. The global hormone refractory breast cancer market is driven by factors such as the increasing incidence of breast cancers, growing aging population, rising demand for advanced therapeutics and presence of large number of pipeline drugs.
Other factors such as growing urbanization and elevated adoption of western lifestyles are also supporting the growth of this market. The global hormone refractory breast cancer market’s growth is also driven by the high demand for novel treatment options for effective management and increasing the lifespan of cancer patients. Geographically, the North America is leading the global hormone refractory breast cancer market, which is followed by the European region. It is anticipated that these two regions will continue to rule the hormone refractory breast cancer market in the forthcoming years. The market forces driving these two regional markets include the large base of patients with hormone refractory breast cancer coupled with huge geriatric population.
In addition to this, the presence of a large number of drug developers in North America and Europe will further support the growth of global market for hormone refractory breast cancer. On the other hand, Asia Pacific will demonstrate a rapid growth in the foreseeable future due to its rapidly-expanding healthcare industry and improved purchasing power of its population. Companies mentioned in the research report Innovation is the key strategy of players in the global hormone refractory breast cancer market. Many companies in the global hormone refractory breast cancer market have their drugs in different stages of clinical trials. Some of the these companies are AstraZeneca plc., AmpliMed Corporation, F. Hoffman-La Roche Ltd., Bluefish Pharmaceuticals AB, NeoCorp GmbH, Bioenvision Limited, Neopharm Ltd., and Boehringer Ingelheim GmbH.